Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$382M |
| 2 |
Pfizer
PFE
|
+$266M |
| 3 |
EA
Electronic Arts
EA
|
+$240M |
| 4 |
Eli Lilly
LLY
|
+$221M |
| 5 |
Colgate-Palmolive
CL
|
+$216M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Booking.com
BKNG
|
+$358M |
| 2 |
Comcast
CMCSA
|
+$263M |
| 3 |
Meta Platforms (Facebook)
META
|
+$258M |
| 4 |
AET
Aetna Inc
AET
|
+$257M |
| 5 |
Tesla
TSLA
|
+$189M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 17.2% |
| 2 | Technology | 14.19% |
| 3 | Financials | 12.33% |
| 4 | Consumer Staples | 10.22% |
| 5 | Industrials | 9.65% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1301
Sasol
SSL
$7.34B
| $9.56M | 0.01% |
341,900
-19,258
| -5% | -$573K |
|
|
JMEI
1302
DELISTED
Jumei International Holding Limited American depositary shares, each representing ten Class A ordina
JMEI
| $9.54M | 0.01% |
447,730
+153,550
| +52% | +$4.68M |
|
|
CHA
1303
DELISTED
China Telecom Corporation, LTD
CHA
| $9.53M | 0.01% |
198,900
+42,300
| +27% | +$2.07M |
|
1304
GeoPark
GPRK
$616M
| $9.49M | 0.01% |
1,262,128
+622,078
| +97% | +$4.78M |
|
1305
Rush Enterprises Class A
RUSHA
$9.6B
| $9.48M | 0.01% |
573,975
+117,499
| +26% | +$1.88M |
|
1306
Ligand Pharmaceuticals
LGND
$5.83B
| $9.48M | 0.01% |
125,185
-36,902
| -23% | -$2.58M |
|
1307
Alexandria Real Estate Equities
ARE
$8.32B
| $9.47M | 0.01% |
+78,600
| New | +$9.15M |
|
1308
Baidu
BIDU
$35.1B
| $9.46M | 0.01% |
52,900
-101,551
| -66% | -$18.4M |
|
1309
Grupo Cibest SA
CIB
$22.9B
| $9.45M | 0.01% |
212,100
+50,000
| +31% | +$2.13M |
|
|
COBZ
1310
DELISTED
CoBiz Financial,Inc
COBZ
| $9.44M | 0.01% |
542,700
+14,900
| +3% | +$245K |
|
1311
Gran Tierra Energy
GTE
$331M
| $9.44M | 0.01% |
421,400
-92,760
| -18% | -$2.25M |
|
|
TSC
1312
DELISTED
TriState Capital Holdings, Inc.
TSC
| $9.43M | 0.01% |
374,200
+61,900
| +20% | +$1.5M |
|
|
LBAI
1313
DELISTED
Lakeland Bancorp Inc
LBAI
| $9.42M | 0.01% |
499,800
+100,900
| +25% | +$1.95M |
|
1314
Performance Food Group
PFGC
$16.8B
| $9.37M | 0.01% |
+341,900
| New | +$9.04M |
|
1315
Peapack-Gladstone Financial
PGC
$822M
| $9.37M | 0.01% |
299,310
+60,972
| +26% | +$1.87M |
|
1316
Stride
LRN
$3.45B
| $9.35M | 0.01% |
522,000
+224,300
| +75% | +$4.3M |
|
|
IVAC
1317
DELISTED
Intevac Inc
IVAC
| $9.35M | 0.01% |
842,344
+331,859
| +65% | +$4.23M |
|
|
MSGN
1318
DELISTED
MSG Networks Inc.
MSGN
| $9.32M | 0.01% |
+415,000
| New | +$9.5M |
|
1319
BP
BP
$110B
| $9.31M | 0.01% |
+302,972
| New | +$9.43M |
|
|
CBPO
1320
DELISTED
China Biologic Products Holdings, Inc.
CBPO
| $9.29M | 0.01% |
82,100
-166,900
| -67% | -$18.7M |
|
1321
Upland Software
UPLD
$16.8M
| $9.28M | 0.01% |
42,200
+24,380
| +137% | +$4.98M |
|
1322
LiveRamp
RAMP
$2.31B
| $9.27M | 0.01% |
356,945
+216,700
| +155% | +$5.89M |
|
1323
Pearson
PSO
$9.75B
| $9.27M | 0.01% |
1,033,200
-291,900
| -22% | -$2.54M |
|
1324
Oil States International
OIS
$545M
| $9.26M | 0.01% |
341,200
+321,200
| +1,606% | +$9.51M |
|
1325
NewMarket
NEU
$8.68B
| $9.26M | 0.01% |
20,100
+900
| +5% | +$415K |
|
Similar funds
Jim Simons's Q2 2017 Portfolio in Review
As of Q2 2017, Jim Simons held 3,586 positions worth $78.4B, up 9.5% from $71.6B the previous quarter. Its ten largest holdings account for 9% of the portfolio.
Jim Simons deployed $4.59B of net new capital in Q2 2017, opening 398 new positions and adding to 1,648 existing holdings. Its largest new stake was Pfizer: 8,421,609 shares worth $268M.
By sector, the portfolio is most concentrated in Healthcare at 17% of assets, up from 16% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was Comcast, an estimated $263M trimmed.
- Jim Simons's largest Q2 2017 buy was Pfizer: 8,421,609 shares worth $268M.
- Jim Simons added most to Bristol-Myers Squibb in Q2 2017, an estimated $382M increase.
- Jim Simons's biggest Q2 2017 reduction was Comcast, cutting an estimated $263M.
- Jim Simons fully exited Booking.com in Q2 2017, selling an estimated $358M.
- Jim Simons's ten largest holdings make up 9% of its $78.4B portfolio in Q2 2017.
- Jim Simons opened 398 new positions and closed 418 in Q2 2017.
- Jim Simons's portfolio value rose 9.5% quarter-over-quarter to $78.4B.
Based on Renaissance Technologies's 13F filing for Q2 2017, filed 11 Aug 2017.